NCT00975936View on ClinicalTrials.gov

Phase 0 Microdose Study

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 21, 2009

Primary Completion Date

November 12, 2009

Study Completion Date

November 12, 2009

Conditions
Autoimmune Diseases
Interventions
DRUG

[14C]-GSK706769

50µg \[14C\]-GSK706769 containing 250 nCi

DRUG

Ketoconazole

200 mg Ketoconazole (Q12)

Trial Locations (1)

53704

GSK Investigational Site, Madison

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY